Please assess the completion status of the following clinical trial:

Trial Title: Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must give a written, signed and dated informed consent~* Chronic plaque-type psoriasis present for at least 6 months before randomization~* Moderate to severe plaque psoriasis as defined at randomization by:~  * PASI score of ≥12 and~ * Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% and~ * IGA mod 2011 ≥3 (based on a scale of 0-4)~* Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:~  * Topical treatment (including topical corticosteroids) and/or~ * Phototherapy and/or~ * Previous systemic therapy~Exclusion Criteria:~* Forms of psoriasis other than plaque psoriasis~* Drug-induced psoriasis~* Ongoing use of prohibited treatments~* Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA, or ustekinumab, or any therapies targeting IL-12 or IL-23~* Use of any other investigational drugs within 5 half-lives of the investigational treatment before study drug initiation~* Pregnant or nursing (lactating) women~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): Secukinumab
- Ustekinumab (Type: ACTIVE_COMPARATOR): Ustekinumab

Based on this trial design, predict the completion outcome and termination type (if applicable).